Anti-atherogenic effect of Humulus japonicus in apolipoprotein E-deficient mice

Int J Mol Med. 2016 Oct;38(4):1101-10. doi: 10.3892/ijmm.2016.2727. Epub 2016 Sep 1.

Abstract

Humulus japonicus (HJ) is used as a traditional medicine in Korea owing to its multiple properties including anti-mycobacterial, antioxidant and antihypertensive effects. The present study aimed to examine the anti‑inflammatory and anti-atherogenic effects of a methanol extract of HJ. In lipopolysaccharide-stimulated RAW 264.7 cells, HJ significantly suppressed the mRNA expression and secretion of pro-inflammatory cytokines [tumor necrosis factor-α, interleukin (IL)-1β and IL-6)], and the release of inflammatory mediators such as nitrite and prostaglandin E2, together with a concomitant decrease in the mRNA levels of inducible nitric oxide synthase and cyclooxygenase-2. To examine whether HJ is capable of inhibiting experimental atherogenesis in an animal model, we randomly divided apolipoprotein E-deficient (apoE-/-) mice into three groups: mice fed an atherogenic diet plus vehicle (0.5% carboxymethyl cellulose) as the control vehicle group, and mice fed an atherogenic diet plus either 100 (HJ100) or 500 mg/kg (HJ500) of HJ as the experimental groups. After 12 weeks of HJ administration, lipid accumulation and the formation of atherosclerotic lesions in the aorta (en face) and the aortic sinus markedly decreased in the HJ500 group compared with the corresponding values in the vehicle control group. Moreover, monocyte and macrophage infiltration in the aortic sinus was markedly reduced in the HJ500 group. Reverse transcription-quantitative polymerase chain reaction analysis of the whole aorta showed that the mRNA levels of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, CD68 and IL-18 were significantly decreased in the HJ500 group. Collectively, these findings suggest that HJ may suppress atherosclerosis by inhibiting lipid accumulation and the expression of pro-atherogenic factors, and it may be effective at preventing the development of atherosclerosis.

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency*
  • Apolipoproteins E / metabolism
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / genetics
  • Atherosclerosis / pathology
  • Cytokines / metabolism
  • Dinoprostone / biosynthesis
  • Gene Expression Regulation / drug effects
  • Humulus / chemistry*
  • Inflammation / genetics
  • Inflammation / pathology
  • Inflammation Mediators / metabolism
  • Macrophages / drug effects
  • Macrophages / pathology
  • Male
  • Mice
  • Monocytes / drug effects
  • Monocytes / pathology
  • Nitrites / metabolism
  • Phytotherapy
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use*
  • RAW 264.7 Cells
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Sinus of Valsalva / drug effects
  • Sinus of Valsalva / pathology

Substances

  • Apolipoproteins E
  • Cytokines
  • Inflammation Mediators
  • Nitrites
  • Plant Extracts
  • RNA, Messenger
  • Dinoprostone